News releases from Allergan plc
Allergan plc (NYSE: AGN) today announced that Chief Commercial Officer William Meury will participate in a fireside chat at the Jefferies 2019 Healthcare Conference in New York, NY. The presentation...
-- Five PLEDGE studies now active and enrolling patients to evaluate the safety and efficacy of relamorelin (investigational drug) in people with diabetic gastroparesis --
Allergan plc (NYSE: AGN) today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the Bernstein 35th Annual Strategic Decisions Conference in New York, NY. The...
Allergan to Present VRAYLAR® (cariprazine) Data at the American Psychiatric Association (APA) 2019 Annual Meeting Highlighting Continued Commitment to Mental Health
May 15, 2019
Abstracts will showcase research on VRAYLAR, including a focus on an investigational use for the treatment of bipolar depression
Allergan plc (NYSE: AGN) today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas,...
Allergan to Present Two Podium Presentations on Bimatoprost Sustained-Release (SR) at The American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
May 03, 2019
-New data will provide insights on treatment duration and biodegradation of the experimental implant in patients with open-angle glaucoma or ocular hypertension-
Allergan Continues to Display Leadership in Neurosciences with 29 Presentations at 2019 American Academy of Neurology Annual Meeting
May 02, 2019
- Allergan MIND™, Allergan's migraine franchise, leads meeting with the most migraine presentations: 24 abstracts highlighting BOTOX® (onabotulinumtoxinA) for Chronic Migraine, ubrogepant and atogepant...
-- Shareholders Approved All Allergan Proposals and Voted AGAINST Shareholder Proposal Calling for Immediate Separation of Chairman and CEO Role --
Allergan to Showcase Continued Eye Care Innovation with New Data at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 25, 2019
- Cincinnati facility generates annual economic output of $46.3 million and total earnings of $28.8 million -
Leading Proxy Advisory Firms ISS and Glass Lewis Support ALL of Allergan Board's Voting Recommendations
April 15, 2019
- ISS and Glass Lewis Recommend AGAINST Appaloosa's Proposal to Immediately Separate Chair and CEO Roles -
Allergan Earns 2019 ENERGY STAR® Partner of the Year - Sustained Excellence Award for the Sixth Consecutive Year
April 10, 2019
Allergan to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast
April 09, 2019
Allergan plc (NYSE: AGN) today announced it will release first quarter 2019 financial results on Tuesday, May 7, 2019, prior to the open of U.S. Financial Markets.
Allergan 360° Aesthetics Report™ Reveals Evolving Beauty Perceptions And Diverse Priorities Around The World
April 08, 2019
Digital Boom and Millennials are Growing the Category, Wellness and Self-Care are New Key Drivers, Interest is in Eyes and Body Contouring
Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol
April 02, 2019
The MAPLE study used a modified manufacturing process and demonstrated decreased intraocular inflammation
Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System to Best-in-Class Medical Aesthetics Portfolio
March 26, 2019
- Proprietary Skin Resurfacing Treatment for the Face and Body Reinforces Allergan's Commitment to Skin Quality -
-- Television Personality is Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment* --
Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients
March 18, 2019
- Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older -
Allergan to Present New Data - "Extended Duration of Intraocular Pressure (IOP) Control with Intracameral Bimatoprost Sustained-Release (SR) Implant" -- Highlighting Clinical Advances at the American
March 14, 2019
- New data to address the treatment duration potential of first-in-class sustained release biodegradable implant -
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
March 11, 2019
- Ubrogepant Seeks to be the First Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for the Acute Treatment of Migraine -
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
March 07, 2019
Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)
March 06, 2019
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Cowen and Company 39th Annual...
Allergan Presents Data From Seven Abstracts At The 2019 American Academy of Dermatology (AAD) in Washington D.C.
February 28, 2019
Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2019 American Academy of Dermatology (AAD) Annual Meeting in Washington D.C. March 1-5, 2019.
Allergan Responds to Public Shareholder Letter
February 19, 2019
Allergan plc (NYSE: AGN) today issued the following statement from its Board of Directors in response to a public shareholder letter:
Robert J. Hugin Appointed to Allergan Board of Directors
February 18, 2019
- Sixth New Director Since 2017 as Part of Allergan's Transformation from a Generic to a Branded Biopharmaceutical Company -
Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 8th Annual SVB Leerink Global...